“Dizlin Pharmaceuticals is very pleased to have entered into an agreement with a well-established and highly reputable pharmaceutical company specializing in the central nervous system – specifically Parkinson’s disease – and with a strong commercial organisation. We are committed to bringing our products to market quickly – and confident of being successful in this regard – so that more patients in the advanced stage of Parkinson’s disease can gain access to this possibility of enhancing their life quality and functioning,” says Björn Velin, CEO of Dizlin Pharmaceuticals.

Infudopa SubC is a ready-to-use levodopa-carbidopa solution delivered via a wearable subcutaneous infusion belt pump. It is designed to provide continuous, precise drug delivery for patients with advanced Parkinson’s Disease (PD) who experience motor fluctuations that are no longer adequately managed by oral medications.

Neuraxpharm’s collaboration with Dizlin is a transformative advancement for PD patients, ensuring access to a therapy that is not only effective but also practical and empowering, it states. Under the terms of this agreement, Neuraxpharm will actively participate in the co-development of the product to ensure its global availability and will receive global exclusive commercialization rights for Infudopa SubC in Europe, countries outside Europe where it has a direct presence, and via partners in other territories, such as US or Japan, to be agreed by both parties.